Business ❯ Finance ❯ Stock Market

Pharmaceutical Stocks

Pfizer Novo Nordisk Tariffs Market Reactions Eli Lilly Market Performance Vertex Pharmaceuticals AstraZeneca Moderna Amgen Sun Pharma Vaccine Manufacturers Sudarshan Pharma Industries Sun Pharmaceutical Ltd. Drug Pricing Policies European Drugmakers Dr. Reddys Laboratories Biotech Stocks SPARC Shares Dr. Reddy's Laboratories Investment Trends Hims & Hers Sarepta Therapeutics Sigachi Industries Dr Reddy's Laboratories Jubilant Pharmova Viking Therapeutics Eli Lilly and Co. Cipla Piramal Pharma Ionis Pharmaceuticals Market Impact AbbVie COVID-19 Vaccine Makers Dr Reddy's Lab Gilead Sciences Lupin Pharmaceuticals Eli Lilly & Company Mira Pharmaceuticals Praxis Precision Medicines, Inc. Novo Nordisk and Eli Lilly Omeros Sangamo Therapeutics Jazz Pharmaceuticals Investment Genmab Stock Teva Pharmaceutical Bristol Myers Squibb Zevra Therapeutics Investor Reactions Emcure Pharmaceuticals COVID Vaccine Manufacturers Rocket Pharmaceuticals Company Performance Hims & Hers Health Market Trends Vaccine Makers Competitor Analysis

Pharvaris’ Oral HAE Drug Deucrictibant Delivers Rapid Relief in Pivotal Phase 3

The company aims to file for FDA approval in the first half of 2026.

Eli Lilly Becomes First Health Care Company Valued at $1 Trillion

FDA Approves Epkinly Monotherapy and Triplet Regimen for Relapsed Follicular Lymphoma

Zymeworks Shifts to Royalty Model After Ziihera’s Phase 3 Win in HER2‑Positive Gastroesophageal Cancer

Teva Tops Q3 Views, Lifts Austedo Outlook as It Narrows Full-Year Sales Range

Eli Lilly Unveils $3 Billion Netherlands Plant for Oral GLP-1 Medicines as Stock Rises

Vertex Tops Q3 Estimates on CF Franchise as New Drugs Miss and Outlook Edges Higher

Praxis Drug Succeeds in Two Phase 3 Essential Tremor Trials, FDA Filing Planned

Mira Pharmaceuticals Soars After Oral Pain Drug Outperforms Morphine in Preclinical Test

Novo Nordisk Licenses Omeros’ MASP-3 Drug in Deal Worth Up to $2.1 Billion

Pfizer–Trump Drug-Pricing Deal and ‘TrumpRx’ Plan Jolt Health-Care Stocks Higher

AbbVie Settlements Push U.S. Rinvoq Generics To 2037

Lilly’s Oral GLP-1 Pill Meets Phase 3 Goals, Shares Rebound

Eli Lilly Raises 2025 Outlook as Tirzepatide Sales Soar, Orforglipron Misses Marks

Pfizer Beats Q2 Estimates and Raises 2025 Profit Forecast

Sarepta Shares Plummet on FDA Review of Elevidys Following Third Patient Death

FDA Halts Rocket’s RP-A501 Gene Therapy for Danon Disease After Patient’s Death